Salt Lake City, Utah-based Recursion Pharmaceuticals (Nasdaq: RXRX) acquired Exscientia, a U.K. firm headquartered in Oxford, in an all-stock deal valued at $688 million. The biotechnology firms use AI to facilitate drug discovery.
To read the entire story, you must be logged in.
Please log in now or register with us.
